Synergy Pharmaceuticals Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 313

Employees
  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 8

  • Investments
  • 2

Synergy Pharmaceuticals General Information

Description

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 420 Lexington Avenue
  • Suite 2012
  • New York, NY 10170
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synergy Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synergy Pharmaceuticals‘s full profile, request access.

Request a free trial

Synergy Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing the
Drug Discovery
New York, NY
313 As of 2017
00000
0000 0000-00-00
000000&0

000000

ulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mo
0000000000000
San Francisco, CA
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00

000000

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Except
000000000000000
Cambridge, MA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synergy Pharmaceuticals Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OrphoMed Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
00000000 000000000 Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
0000000 0000000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
You’re viewing 5 of 36 competitors. Get the full list »

Synergy Pharmaceuticals Patents

Synergy Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160367623-A1 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders Abandoned 16-Jun-2015 000000000
US-20150273013-A1 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders Abandoned 25-Mar-2014 000000000
US-20200009215-A1 Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions Abandoned 10-Oct-2013 000000000
US-20160367622-A1 Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions Abandoned 10-Oct-2013 000000000
US-20140187470-A1 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders Abandoned 02-Jan-2013 A61K45/06
To view Synergy Pharmaceuticals’s complete patent history, request access »

Synergy Pharmaceuticals Executive Team (8)

Name Title Board Seat Contact Info
Leslie Magnus MD Senior Vice President, Medical Affairs
Troy Hamilton Chief Executive Officer & Director
Gary Gemignani Executive Vice President & Chief Financial Officer
Marino Garcia Chief Strategy Officer & Executive Vice President
Dan Dunham JD Senior Vice President & Chief Compliance Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Synergy Pharmaceuticals Board Members (4)

Name Representing Role Since
000000 00000 00.0 Self Board Member 000 0000
You’re viewing 1 of 4 board members. Get the full list »

Synergy Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synergy Pharmaceuticals Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Synergy Pharmaceuticals‘s full profile, request access.

Request a free trial

Synergy Pharmaceuticals Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 17-Jan-2013 0000000000 00000 Pharmaceuticals
Pawfect Foods 21-Jul-2008 Merger/Acquisition Internet Retail 0000 0000
To view Synergy Pharmaceuticals’s complete acquisitions history, request access »